Abstract Tumor growth depends on the formation of new blood vessels (tumor angiogenesis) either from preexisting vessels or by the recruitment of bone marrow-derived cells. Despite encouraging results obtained with preclinical cancer models, the therapeutic targeting of tumor angiogenesis has thus far failed to deliver an enduring clinical response in cancer patients. One major obstacle for improving antiangiogenic therapy is the lack of validated biomarkers, which allow patient stratification for suitable treatment and a rapid assessment of therapy response. Toward these goals, we have employed several mouse models of tumor angiogenesis to identify cell populations circulating in their blood that correlated with the extent of tumor angiogenesis and therapy response. Flow cytometry analyses of different combinations of cell surface markers that define subsets of bone marrow-derived cells were performed on peripheral blood mononuclear cells from tumor-bearing and healthy mice. We identified one cell population, CD45 dim-
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VEGFR1
-CD31 low , that was increased in levels during active tumor angiogenesis in a variety of transgenic and syngeneic transplantation mouse models of cancer. Treatment with various anti-angiogenic drugs did not affect CD45 dim VEGFR1 -CD31 low cells in healthy mice, whereas in tumor-bearing mice, a consistent reduction in their levels was observed. Gene expression profiling of CD45 dim VEGFR1 -CD31 low cells characterized these cells as an immature B cell population. These immature B cells were then directly validated as surrogate marker for tumor angiogenesis and of pharmacologic responses to anti-angiogenic therapies in various mouse models of cancer.
Keywords Anti-angiogenic therapy Á B cell Á Biomarker Á Cancer Á Tumor angiogenesis angiogenesis to pro-angiogenic activities [1] . Specifically, neo-angiogenesis involves the sprouting, migration and proliferation of endothelial cells from preexisting blood vessels or the formation of capillary sprouts by intussusception [2, 3] . Angiogenesis is controlled by several soluble factors, such as placental growth factor (PlGF), fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), angiopoietins, ephrins, semaphorins, interleukins and other chemokines [4] and, most importantly, vascular endothelial growth factor A (VEGF-A), the central player in both physiological and pathological angiogenesis [5] [6] [7] ). Pro-angiogenic factors are produced by both neoplastic and stromal cells in the tumor microenvironment [8] [9] [10] [11] . On the other hand, during the angiogenic switch, a number of endogenous angiogenesis inhibitors, such as thrombospondin, are reduced in their expression levels [12] . The search for valid biomarkers of the angiogenic switch and ongoing tumor angiogenesis has revealed that bone marrow-derived CD45
? leukocytes infiltrating the tumor microenvironment can be used to assess patients' clinical outcome in melanoma and in colorectal, mammary, lung and ovarian carcinomas [13] [14] [15] [16] [17] . While several studies suggest an anti-tumorigenic role for leukocytes, a plethora of studies demonstrate a critical role for them in cancer initiation and progression [18, 19] . Notably, different leukocyte subsets have been shown to be involved in vascular remodeling and new blood vessel formation [20] . Importantly, innate immune cells have been clearly proved to be involved in the process of tumor angiogenesis mainly by their recruitment to the tumor site and the secretion of a cocktail of pro-angiogenic factors [21] [22] [23] [24] [25] [26] [27] . On the other hand, non-hematopoietic CD45 dim/negative endothelial precursors cells (EPC) can be mobilized from the bone marrow and transported in the blood stream to the tumor site where they are incorporated into the wall of growing blood vessel, thus contributing to tumor angiogenesis [8] . However, due to the absence of highly specific cell surface markers used to identify EPCs, there are conflicting data whether and to what extent these cells are incorporated into the vessel wall and eventually contribute to tumor angiogenesis [8, 9, 28, 29] .
Anti-angiogenic therapy mainly targets blood vessels in the tumor with the aim to impede tumor growth and metastasis formation. The critical role of the VEGF-A/ VEGF receptor-2 (VEGFR-2) signaling axis in the onset of tumor angiogenesis has led to the development of several drugs targeting this pathway. An example is bevacizumab (Avastin Ò ), a humanized antibody neutralizing VEGF-A with varying efficacy in different cancer types [30] [31] [32] . Apparently, in some cancer types, VEGF-A is not the only factor inducing tumor angiogenesis, such as in breast cancer. Moreover, interfering with VEGF-A signaling in most cases resulted in resistance development by the compensatory production of other angiogenic factors by tumor cells and/or stromal cells [33] , for example, by tumor-infiltrating Th17 cells providing proangiogenic IL17 [34] . Thus, strategies to overcome resistance to single-targeted anti-angiogenic agents include the development of novel compounds that target tumor angiogenesis and thus tumor growth through multiple pathways [35] .
Obviously, the possibility to monitor in a longitudinal and noninvasive manner ongoing tumor angiogenesis in patients and their responses to anti-angiogenic therapies would be beneficial for efficient anti-angiogenic cancer therapy. Hence, the discovery of reliable biomarkers seems essential to predict the response of anti-angiogenic therapy and the development of resistance to anti-angiogenic therapy in patients. An example is the measurement of circulating levels of VEGF-A, FGF-2, HGF and IL-8, which, however, reliably predicted survival only in some models [36] . Furthermore, levels of circulating endothelial cells (CECs) and EPCs increase in blood during tumor angiogenesis or other vascular diseases and, therefore, could also be employed as surrogate markers [8, [36] [37] [38] . In addition, as described above, bone marrow-derived cell populations also may have the potential to serve as surrogate markers for monitoring tumor angiogenesis and antiangiogenic therapies.
Here, we report that the levels of a bone marrow-derived cell population, CD45 dim VEGFR1 -CD31 low , were increased in peripheral blood in a variety of mouse models of tumor angiogenesis in comparison with healthy mice. These high levels in tumor-bearing mice were reduced upon treatment with the anti-angiogenic compound PTK787/ZK222584 (PTK/ZK) that interfered with VEGF receptor signaling. Surprisingly, treatment for longer time periods re-established the levels of the cell population in the peripheral blood which correlated with therapy resistance and tumor regrowth. In contrast, long-term treatment using compounds that in addition to VEGF also inhibited FGF and PDGF (BIBF-1120, nintedanib) led to a significant decrease in the levels of CD45 dim VEGFR1
--CD31 low cells in the blood of tumor mice as well as a reduction in tumor volume and microvessel densities. Gene expression profiling identified CD45 dim VEGFR1 -CD31 low cells as an immature B cell population. Subsequent direct analysis validated the correlation between the levels of the immature B cell population in peripheral blood with ongoing tumor angiogenesis and with a response to anti-angiogenic therapies in different mouse models of cancer. This cell population thus may serve as surrogate marker for tumor angiogenesis and for the response to anti-angiogenic therapy.
Materials and methods

Mouse lines
All experimental procedures involving mice were approved by and conducted according to the guidelines and regulations of the local committees for animal care (The Swiss Federal Veterinary Office (SFVO) and the Cantonal Veterinary Office of Basel-Stadt, permit numbers 1878, 1907, 1908, 2137) . Generation and phenotypic characterization of Rip1-Tag2 (RT2) and MMTV-PyMT mice have been described previously [39] [40] [41] . In RT2 mice, tumor incidence was determined per mouse by counting of all macroscopically visible pancreatic tumors with a diameter above 1 mm and the tumor volume was calculated from the measured tumor diameter assuming a spherical tumor. In MMTV-PyMT mice, tumor volume per mouse was calculated as the total weight of all tumors dissected form each mouse. C57BL/6-Tg(ACTB-EGFP) mice [42] were provided by G. Hollän-der (University of Basel).
Tumor transplantation models 5 9 10 5 TRAMP-C1 cells [43] (provided by N. Greenberg, FHCRC, Seattle) were injected into the flank of 6-week-old C57BL/6 mice and grown for 3-4 weeks [29] . 5 9 10 5 Py2T cells [44] were injected into mammary fat pad of 6-to 10-week-old FVB/N mice and grown for 5 weeks. 1 9 10 6 4T1 cells [45] were injected into mammary fat pad of 6-week-old BALB/c mice and grown for 5 weeks.
Two-dimensional (2D) cultured MTflECad cells [46] were injected as a single-cell suspension in PBS at defined cell numbers into the ninth mammary gland of 7-to 10-week-old female BALB/c Rag2 -/-; common c receptor -/-(Rag2 -/-/cc -/-; RG) mice [47] .
Bone marrow transplantations
Bone marrow cells were extracted under sterile conditions from femurs and tibiae of donor C57BL/6-Tg(ACTB-EGFP) mice. After T cell depletion [48] , 5 9 10 6 cells were injected in the tail vein of lethally irradiated (26550 cGy) 6-week-old RT2 mice, which were then killed for further analysis after 5-7 weeks of transplantation as reported elsewhere [29] .
Anti-angiogenic treatments
RT2 or MMTV-PyMT mice were treated with either 100 mg/kg body weight PTK787/ZK222584 (PTK/ZK), dissolved in PEG-300 (Sigma, St. Louis, MO, USA) [49, 50] or with 100 ll/10 g body weight of PEG-300 alone (vehicle control) by daily oral administration for 5 days. For RT2 mice, the treatment started at the age of 8-9 or 12 weeks and for MMTV-PyMT mice started at 10 weeks. In addition, RT2 mice were treated for 10 days or 3 weeks starting at age 10 or 9 weeks, respectively. PTK/ZK was kindly provided by Novartis Pharma.
RT2 mice were treated with either 50 mg/kg body weight BIBF-1120 (nintedanib) dissolved in 0.5 % Natrosol (Sigma) [51] or 0.5 % Natrosol 100 ll/10 g body weight alone by daily oral administration for 5 days or 3 weeks starting at the age of 12 or 9 weeks, respectively. BIBF-1120 was kindly provided by Boehringer Ingelheim.
RT2 mice were treated with either 40 mg/kg body weight sunitinib malate (Sutent, S-8803, LC Laboratories, MA, USA) dissolved in sodium carboxymethylcellulose (Sigma) (CMC) solution (CMC: 0.5 %, NaCl 1.8 %, Tween 80 0.4 %, and benzyl alcohol 0.9 % in distilled water) or CMC 100 ll/10 g body weight alone by daily oral administration for 5 days or 3 weeks starting at the age of 12 or 9 weeks, respectively [52, 53] .
Recombinant E1/E3-defective adenovirus expressing EGFP (Adenovirus-GFP) or soluble sFGFR2 (Adenovirustrap-FGFR) was used as previously described [54, 55] . For the treatment of RT2 mice, 10 10 virus particles/200 ll were injected into the tail vein once a week for 2 weeks, starting at the age of 10 weeks. In a combination regimen, RT2 mice were treated with either 100 mg/kg body weight PTK/ZK or PEG-300 100 ll/10 g body weight alone by daily oral administration for 10 days starting at the age of 10 weeks followed by 10 10 virus particles/200 ll Adenovirus-trap-VEGFR2 or Adenovirus-GFP or Adenovirustrap-FGFR tail vein injection once a week for 2 weeks.
Tumor-transplanted Py2T-FVB/N and 4T1-Balb/c mice were treated with either 50 mg/kg body weight BIBF-1120 or 0.5 % Natrosol 100 ll/10 g body weight alone by daily oral administration for 3 weeks starting when tumors reached measurable size.
Purification of PBMNCs from total blood
Total blood was drawn by heart puncture of euthanized mice or tail vein bleeding of living mice, diluted with one volume of PBS, and mixed. Two volumes of Hystopaque-10771 (Ficoll) (10771, Sigma) were added beneath diluted blood with a glass Pasteur pipette followed by centrifugation for 45 min at RT without brake at 6509g. After the gradient separation, peripheral blood mononuclear cells (PBMNCs) were residing in a ring between plasma (top) and Ficoll (bottom). The ring with PBMNCs was collected, washed twice with 2 ml of FACS buffer (5 % FBS serum in PBS 19) , and the cells were counted.
Organ and tumor dissection
Spleen and lymph node were dissected from mice and kept in ice-cold PBS. The organs were minced, passed through a 70-lm cell strainer (352350, BD Bioscience, NJ, USA). Cells were collected (in PBS) and washed once in PBS. Erythrocyte lysis was performed with red blood cell (RBC) lysis buffer (NH 4 Cl 1.5 M, KHCO 3 0.1 M, EDTA 2.5 mM) for 10 min at RT and blocked with two volumes of PBS. Cells were then resuspended in FACS buffer and counted. Bone marrow was flushed from femurs and tibiae of mouse hind limbs with PBS, washed in PBS, and erythrocyte lysis was performed. Cells were resuspended in FACS buffer and counted.
Histopathological analysis
For histopathological analysis, the isolated organs were fixed in 4 % paraformaldehyde (Sigma) for 2 h at 4°C and then incubated over night in 20 % sucrose in PBS at 4°C and finally embedded in OCT (Tissue Tek, AGR1180, Agar Scientific, UK). Immunostainings were performed on 7-lm cryosections. After cutting, tissue sections were placed on slides, washed with PBS and then blocked for 60 min at RT or over night at 4°C with 5 % goat serum in PBS (blocking buffer). Afterward, the sections were incubated for 60 min with rat anti-mouse CD31 (550274, BD Pharmingen, NJ, USA) diluted in blocking buffer, washed with PBS and incubated with the secondary antibody diluted in blocking buffer. After 30 min, sections were washed with PBS, nuclei were counterstained with DAPI (09542, Sigma), and slides were mounted with Mowiol (Sigma).
Flow cytometric analysis
Cells were washed in FACS buffer, Fc-blocked with a monoclonal antibody against mouse CD16/CD32 (dilution 1:100, Clone 93, 1-01302 BioLegend, CA, USA) for 10 min at RT and then stained for 30 min, at 4°C in dark with conjugated antibodies of interest which were diluted in FACS buffer. Cells were then washed twice in FACS buffer and filtered through a filter with 40 lm pore size. Propidium Iodide (PI) (dilution 1:100, P4170, Sigma, St. Louis, MO, USA) or 6-diamidino-2-phenylindole (dilution 1:100, DAPI) was added to exclude dead cells immediately before analysis on a FACS Canto II (BD Bioscience, NJ, USA) or cell sorting on a FACS Aria II (BD Bioscience). 
Real-time PCR
Total RNA was extracted from total tumors of 5 or 10 days PTK/ZK or PEG-300 treated RT2 mice using RNAeasy Mini Kit (74104, QIAGEN, Dusseldorf, Germany). Firststrand cDNA was synthesized from 1 lg RNA using ImProm-II Reverse Transcriptase (M314C, Promega, Madison, WI, USA). Quantitative PCR for mouse Vegfa, Vegfr1, Vegfr2, Vegfr3, Nrp1, Nrp2, Cd31, Fgf1, Fgf2 and Hif1a was done on a Step One Plus (Applied BiosystemsLife Technologies, Carlsbad, CA, USA) using a SYBR Green PCR MasterMix (Mesa Green qPCR MAsterMix Plus, Eurogentec, Liege, Belgium) and normalized versus mouse ribosomal protein 19 (mRPL19) transcript levels.
Gene expression profiling
PBMNCs were prepared by Hystopaque gradient from two different groups of 12-week-old RT2 mice and pooled within each group to get a biological duplicate. For subsequent isolation by flow cytometry, cells were first Fcblocked with a monoclonal antibody against mouse CD16/ CD32 and then stained with rat anti-mouse CD45 APC, rat anti-mouse VEGFR1 PE and rat anti-mouse CD31 FITC. CD45 dim VEGFR1 -CD31 low cells were then isolated on a FACS Aria II. Total RNA was extracted from isolated cells using the Absolutely RNA Nanoprep Kit (Stratagene, CA, USA), amplified in two rounds (NuGen, CA, USA), IVTlabeled, fragmented and hybridized to GeneChip Ò Mouse 2.0 st microarray (Affymetrix, CA, USA).
Bioinformatics analysis
Gene expression profiles were background corrected and normalized using the RMA algorithm and subjected to quality control. The distribution of log2 expression values for each replicate as a mixture of two normal distributions (non-expressed and expressed genes) was modeled using the mclust package, with G = 2 and modelNames = ''V'' [56] . Allowing for 5 % of false positives, a single cutoff for each replicate was defined. Genes with expression values above these thresholds in all replicates were classified as expressed in a given cell stage. The top 25 % of genes were selected based on their normalized absolute expression value. The resulting list of genes was subsequently subjected to GO term and pathway enrichment analysis using GeneCodis and Ingenuity Pathway Analysis (IPA), respectively.
HUVEC co-culture experiments
high cells were FACS-sorted from PBMNCs purified from fifteen 12-week-old RT2 mice. 10 5 sorted cells were mixed with 4 9 10 3 HUVECs and plated on top of growth factor-reduced Matrigel (356230, BD Bioscience) in lSlide Angiogenesis slides (81506, ibidi GmbH, Germany) in different media: EBM-2 basal (CC-3156, Lonza, Switzerland) or EGM-2 which is EBM-2 medium supplemented with growth factors (CC-3202, Lonza). Pictures were taken after 1.5, 2.5, 5, 6, and 17 h with a Leica DMI 4000 inverted microscope and analyzed using Image J (Angiogenesis analyzer plug-in).
Statistical analysis
All data are presented as means with standard errors of the mean (SEM) unless otherwise indicated. The MannWhitney t test (unilateral, unpaired, nonparametric test) was used for two-groups experiments and ANOVA for three-groups experiments. All statistical computations were done using GraphPad Prism v6.0c (GraphPad, La Jolla, CA, USA). Results were considered statistically significant when the P value was [0.05.
Results
The levels of CD45 dim VEGFR1 2 CD31 low cells are increased in tumor-bearing mice
In the initial experimental approaches, we have employed the RT2 transgenic mouse model of pancreatic b-cell carcinogenesis to screen for cell populations circulating at high levels in the peripheral blood of tumor-bearing mice [39] . In RT2 mice, the rat insulin promoter 1 (Rip1) drives expression of SV40 large T antigen (Tag) in insulin-producing pancreatic b-cells. Several tumor stages can be distinguished, including normal islets, b-cell hyperplasia, adenoma and carcinoma. Notably, hyperplastic islets can be classified into two types: non-angiogenic islets that do not affect co-cultured endothelial cells and angiogenic islets that are able to induce proliferation, migration, and tube formation of endothelial cells [57] . Based on these experiments, it has been proposed that soluble factors are involved in the onset of tumor angiogenesis (the angiogenic switch). In subsequent years, these mice have been used by us and others in a large number of studies for the functional characterization of pro-angiogenic factors (reviewed in [12] ). To assess the generality and applicability of the findings, the MMTV-PyMT transgenic mouse model of metastatic breast cancer and syngeneic TRAMPC1-C57BL/6 mouse model of prostate cancer were also employed.
These mouse models were used for the identification of cells that correlate in their numbers in the peripheral blood with ongoing tumor angiogenesis (Supplementary Figure 1A) . Peripheral blood was taken from these mice, and the levels of specific subpopulations of circulating cells in tumor-bearing mice as compared to healthy C57BL/6 mice were assessed by fluorescent staining of PBMNCs with combinations of antibodies defining certain subsets of EPCs, CECs and many other subtypes of bone marrow-derived mononuclear cells and subsequent flow cytometry analysis as detailed according to a previous report in Supplementary Figure 1B [8] . Since these surface markers are not exclusive for EPCs and CECs and are also expressed on other cell types, such as lymphocytes, myeloid cells and haematopoietic progenitor cells, we have used additional antibodies and combinations thereof to detect by flow cytometry particular cell populations in peripheral blood of mouse models of tumor angiogenesis in comparison with non-tumor-bearing mice (Supplementary Figure 1B) .
By testing single markers and combinations of markers, four cell populations were identified whose levels correlated with tumor angiogenesis in 12-week-old RT2 mice (Fig. 1a-e) , 10-week-old MMTV-PyMT mice and syngeneic TRAMPC1-C57BL/6 mice ( Supplementary Figure 2) . The four cell population levels were expressed as percentage of singlets and named on the basis of expression of the markers used for their identification:
and TEMs (TIE2-expressing monocytes, TIE2
? CD45 ? cKit -CD11b ? CD31 low ) (Fig. 1b-e) . Their levels were significantly higher in 12-week-old RT2 and in 10-week-old MMTV-PyMT mice in comparison with healthy C57BL/6 and FVB/N mice, respectively ( Fig. 1b-e; Supplementary Figure 2A) .
The levels of the VR2 ?
TIE2
?
VR1
-cell population in all mouse cancer models were found to be more variable and their correlation with tumor angiogenesis was less Figure 2B) . Besides, the 
CD31
low cell populations were increased in 8-to 9-week-old RT2 mice, when the tumors were small and had only recently undergone an angiogenic switch, compared to healthy mice of the same age (Supplementary Figure 2C) . These analyses suggest that CD45 dim
VR1
-and its subpopulation, CD45 dim VR1 -CD31 low , are consistently elevated during tumorigenesis in a variety of mouse cancer models. These populations thus may serve as surrogate markers to monitor early and late stage tumorigenesis in mouse models. 
cells decrease upon antiangiogenic therapy
To investigate whether the cell populations described above are indeed good candidates as surrogate markers for tumor angiogenesis, tumor-bearing mice (12-week-old RT2 or 10-week-old MMTV-PyMT mice) were treated with different anti-angiogenic drugs, such as PTK/ZK (an inhibitor for all three VEGF receptors, all PDGF receptors, c-Kit and c-Fms), BIBF-1120 (nintedanib; inhibits all three VEGF receptors, PDGF receptors, all FGF receptors, FLT3 and members of the SRC-family [51] ), and sunitinib malate (inhibits all PDGF receptors, VEGF receptor 1 and 2, c-Kit, FLT3 and RET; Fig. 2a ). All the therapeutic regimens significantly reduced the tumor volume and microvessel density in tumor-bearing mice (Supplementary Figure 3A- C, data not shown). Peripheral blood was drawn from the treated mice, and the levels of the CD45 dim VR1 -and CD45 dim-
VR1
-CD31 low cell populations were assessed by flow cytometry (Fig. 2b-d) . After 5 days of PTK/ZK (Fig. 2b) , BIBF-1120 (Fig. 2c) or sunitinib (Fig. 2d ) treatment, the levels of the two cell populations were significantly diminished as compared to placebo-treated mice and to levels found in peripheral blood of healthy mice (Fig. 1) . Five days of PTK/ZK treatment in MMTV-PyMT mice also led to a significant decrease in the levels of CD45 dim VR1 -and CD45 dim VR1 -CD31 low cell populations (Fig. 2e) . To assess whether a similar effect could also be observed for younger mice with early-stage cancer, a ''short-term intervention trial'' with PTK/ZK or BIBF-1120 was performed with 8-to 9-week-old RT2 mice. A 5-day treatment reduced tumor growth and microvessel densities (data not shown) and concomitantly decreased the cell populations in the peripheral blood of PTK/ZK-treated mice as compared to placebotreated mice (Fig. 2f) . These data indicate that anti-angiogenic therapy in RT2 mice and 10-week-old MMTV-PyMT mice leads to a repression of tumor angiogenesis and tumor growth [59] and concomitantly reduces the levels of CD45 dim VR1 -and CD45 dim VR1 -CD31 low cells circulating in the peripheral blood of tumor-bearing mice. 
-CD31 low cells remained unaltered in the peripheral blood of RT2 mice after such longer treatment (Fig. 3a) , although tumor growth and microvessel densities were efficiently reduced (Supplementary Figure 4A) . Since it is well established that therapies targeting the VEGF signaling axis can lead to the upregulation of a panel of pro- inflammatory and pro-angiogenic growth factors [34, 52, 53] , we assessed whether the returning increase in the cell populations between a 5-day and a 10-day PTK/ZK treatment could reflect compensatory mechanisms overcoming the inhibitory activity of PTK/ZK, for example, by the activities of other angiogenic factors. Indeed, the levels of mRNAs encoding for Fgf1, Fgf2 and Vegf-a were increased in tumors between 5-and 10-day treatment of RT2 mice with PTK/ZK (Supplemental Figure 4B) population levels were high after 10 days of PTK/ZK treatment; however, they were abated significantly upon the subsequent blockade of FGF signaling (Fig. 3b) . Intratumoral vessel density was also diminished compared to control mice; however, tumor volumes were non significantly increased upon Adenovirus-trap-FGFR treatment, an observation that may involve non-angiogenesisrelated effects on tumor growth and needs further investigations (Supplementary Figure 4C) .
To validate these findings, RT2 transgenic mice and Py2T-FVB/N and 4T1-BALB/c tumor-bearing mice were treated for 3 weeks with BIBF-1120 (nintedanib; Fig. 4a-c) . The CD45 dim VR1 -and CD45 dim VR1 -CD31 low cell populations in the peripheral blood of the various BIBF-1120-treated mouse cancer models were significantly decreased compared to vehicle-treated mice. As expected, tumor growth and intra-tumoral vessels were substantially reduced by treatment with BIBF-1120 (data not shown). Notably, the lower levels of CD45 dim VR1 -and CD45 dim VR1 -CD31 low cells in the peripheral blood of healthy mice were not altered upon short-term PZK/ZK treatment or short-or long-term treatment with BIBF-1120 (Fig. 5a, b) , and thus the drugs were not directly targeting the cell populations as such. Also, the extensive microvasculature present in normal islets of Langerhans was not affected by either treatment, and hence the drugs were targeting exclusively active pathological angiogenesis (Supplementary Figure 5) .
CD45
dim VR1 2 CD31 low cells represent bone marrow-derived immature B cells
To determine the cell lineage of the CD45 dim VR1 -CD31 low cell population, lethally irradiated RT2 mice were transplanted with bone marrow isolated from actin-GFP transgenic mice [29, 42] . Flow cytometry analysis of peripheral blood showed an efficient hematopoietic reconstitution of the hematopoietic system with about 70 % chimerism in the transplanted mice and demonstrated that the CD45 dim VR1
and CD45 dim VR1 -CD31 low cell populations were GFP-positive, indicating that they originated from bone marrow (Fig. 6a) . CD45 dim VR1 -and CD45 dim VR1 -CD31 low cells not only circulated in peripheral blood, but were also found in spleen, lymph node and, with lower incidence, in tumors of RT2 mice (Fig. 6b) . Thus, CD45 dim VR1
and CD45 dim VR1
-CD31 low are PBMNCs that are mobilized from the bone marrow in response to angiogenic stimuli generated by tumor cells or cells of the tumor stroma in the RT2 transgenic mouse model.
To determine the cell lineage identity of the potential surrogate marker cell population, CD45 dim VR1 -CD31 low cells were isolated by flow cytometry sorting from peripheral blood of RT2 mice and subjected to gene expression profiling by Affymetrix Chip analysis. R and Ingenuity Pathway Analysis (IPA) pinpointed that many genes of the CD45 dim VR1 -CD31 low transcriptome were clustered in five classes within the Physiological System Development and Function categories in IPA ( Fig. 7a ; Online Resource 1, Online Resource 2). Among those classes were hematopoiesis, lymphoid tissue structure and hematological system development and function. Furthermore, in the canonical pathways as defined by IPA, a high degree of coverage of pathway gene members was found to belong to B cell receptor signaling (Fig. 7b) .
B cell development is initiated in the fetal liver before birth and in the bone marrow in adults, yet subsequent functional maturation occurs in secondary lymphoid organs. B cells that have exited the bone marrow migrate to the spleen where they undergo further maturation via transitional stages identified by the expression of markers such as CD21 (CD23 in the mouse) and eventually reaching the final maturation as follicular B cells. T celldependent immune responses induce additional germinal center (GC) maturation in secondary lymphoid organs. B cells in peripheral compartments may also belong to more specialized B cell subsets including CD5
? B1 cells, which have a role in tumor angiogenesis [61] , or marginal zone (MZ) B cells. Germinal center maturation of B cells leads to the generation of memory B cells and the development of antibody secreting plasma cells ( Supplementary Figure 6A ) [62] [63] [64] [65] .
IPA analysis also generated a list of genes specifically localized in the plasma membrane or in the extracellular space 
IgM
? cells were negative for IgD, identifying them as an immature B cell population (Fig. 7c, Supplementary Figure 6A 
IgD
-cells were about 70-80 % CD21 negative (Supplementary Figure 6C) , confirming their immature phenotype. In addition, they did not express CD5 (data not shown), indicating they did not represent a specialized B cell subset named B1 cells [65] .
To further validate CD45 
MannWhitney test: ***P \ 0.005; ****P \ 0.001. N = number of mice; V = vehicle; B = BIBF-1120
Angiogenesis (2015) IgD -cell subpopulations were found reduced in BIBF-1120-treated RT2 mice (Fig. 7d) . Moreover, immunofluorescence microscopy analysis of tumors from 12-week-old RT2 mice (Supplementary Figure 7A) as well as flow cytometry analyses (Supplementary Figure 7B) showed that immature B cells were sporadically infiltrating tumors of 12-week-old RT2 mice. In addition, since immature B cells mobilize from bone marrow to spleen to complete their maturation, the presence of our population of interest in bone marrow and in spleen validated their immature phenotype.
Immature B cells promote endothelial cell to form cord-like structures
In order to obtain a first glimpse into a potential func- (Fig. 8) . These results raise the possibility that immature B cells, mobilized by ongoing tumor angiogenesis and repressed in numbers by anti-angiogenic therapy, may not only serve as surrogate marker for tumor angiogenesis but may also indirectly support tumor angiogenesis. However, the latter notion requires further validation in mouse models in vivo.
Discussion
The development of predictive biomarkers for anti-angiogenic therapies is urgently needed to select those patients who most likely will benefit from anti-angiogenic therapy and to prevent unnecessary loss of time and toxicity in therapy-resistant patients. Despite numerous attempts, thus far no validated biomarker to monitor ongoing tumor angiogenesis is available for routine clinical use. For example, elevated levels of VEGF in tumors are known to correlate with advanced clinical stage and poor prognosis; however, analyses of VEGF expression levels in tissue samples of breast and colorectal cancer treated with bevacizumab do not predict response to anti-angiogenic therapy [66] . An example of a functional parameter used as biomarker is tumor microvessel density. It reflects the amount of vascularization in tumors and, thus, is a good prognostic factor, yet it has failed as a predictive biomarker for treatment response in clinical settings. As cellular biomarkers, the numbers of CECs and EPCs in the blood correlate with angiogenesis and tumor progression, and their increased levels return to normal following anti-angiogenic treatments [67] . However, in certain type of cancers, these numbers have not correlated with the efficacy of anti-angiogenic therapies and, therefore, reproducibility and standardization of these approaches are challenging if not limiting for routine clinical use [68] . It is thus critical to identify a reliable prognostic and predictive biomarker for tumor angiogenesis.
Here, we report the identification of CD45 dim VR1 
IgD
-cells may serve as surrogate markers for the status of tumor angiogenesis in many different mouse models of cancer and with varying anti-angiogenic regimen.
However, upon variation of the duration of different anti-angiogenic therapies, we observed that the specific targeting of only one angiogenic signaling pathway resulted only in a short-term reduction in the surrogate marker cell population. For example, interfering with VEGF signaling alone by PTK/ZK or a neutralizing antibody to VEGF receptor 2 (DC101; data not shown) failed to reduce the cell population levels in peripheral blood of RT2 mice after long-term treatment, despite a substantial reduction in microvessel densities and tumor growth. Specifically, we observed a reduction in the CD45 dim-
VR1
-CD31 low cell population in peripheral blood of RT2 mice after 5 days but not after 10 days of PTK/ZK treatment. We suspect that the re-establishment of higher levels of CD45 dim VR1 -CD31 low cells may indicate the development of resistance against the mono-target therapies. In fact, it has been previously reported that already 1 week of treatment of RT2 mice with DC101 leads to tumor hypoxia and the subsequent upregulated expression of FGF, VEGF and Ang2 resulting in more vascularized and invasive tumors [52, 53] . We found that the 10-day treatment of RT2 mice with PTK/ZK also promoted the expression of the angiogenic factors FGF1 and FGF2, and we treated the mice with Adenovirus-trap-FGFR-trap for 2 weeks and found a further decrease in microvessel densities as well as a reduction in the levels of CD45 dim VR1 -CD31 low cells in comparison with RT2 mice treated with PTK/ZK for 10 days alone. Thus, the augmented levels of CD45 dim-
-CD31 low cells in RT2 mice treated for 10 days could be a first sign of evasive resistance to this drug mainly targeting VEGF receptors only, supporting the hypothesis that this cell population could be a good predictive marker of anti-angiogenic therapy response.
In contrast to the mono-target therapies, the levels of CD45 dim VR1 -CD31 low cells remained reduced upon longterm treatment of RT2 mice with the multi-kinase inhibitor BIBF-1120 (nintedanib), suggesting that it exerts a highly effective and sustainable anti-angiogenic activity. [52, 69] . Thus, the nature of the possible pro-angiogenic activity of our cell population of interest, most likely exerted by secreted pro-angiogenic factors, remains to be further investigated, notably in mouse models in vivo.
Gene expression profiling and flow cytometry analysis classified the CD45 dim VR1 -CD31 low cell population as immature B cells, positive for the B cell lineage markers B220, CD19 and IgM and negative for IgD, CD23 and CD21. Although the immature B cells were found to be bone marrow-derived and circulating in the blood, they were also present in spleen and at very low levels in lymph nodes and in tumors. The low percentage detected in lymph nodes of RT2 mice support the findings that the surrogate marker cell population indeed exhibits an immature phenotype, since only mature B cells are known to localize to lymph nodes [70] . Furthermore, the localization in spleen indicated the possibility that the cell population could complete its development to mature B cells. However, further studies are warranted to address whether the CD45 dim VR1 -CD31 low cells are able to complete maturation to B cells and what their functional role in tumor angiogenesis in vivo could be.
Indeed, several reports have described the dual role of immune system in tumor progression and angiogenesis [11, 71] . The majority of the studies have focused on tumorinfiltrating cells of the immune system and are crucial mediators of cancer initiation and progression. For instance, B cells have been found in aggregates with other immune cells in several human cancer types [72] . Although various studies have demonstrated the beneficial effects of B cells tumor infiltration on anticancer immunity [73] , it has been reported that B cells are required for de novo carcinogenesis in mouse models of skin cancer [74] and that B cells producing TNFa are important in papilloma development [75] . Yang et al. [76] have shown that B cells with activated STAT3 signaling produce pro-angiogenic factors resulting in increased angiogenesis and accelerated tumor progression. Furthermore, B220
low IgM high CD11b
(so-called B1 cells [77] ) have been found to drive M2-like polarization of macrophages and to promote the growth of transplanted B16 melanoma [61] . Thus, the immature B cell surrogate marker population we have identified may exert an indirect role in tumor angiogenesis, comparable to the B1 cell subpopulation, which they closely resemble according to their B cell marker expression.
Increased levels of CECs, EPCs and bone marrowderived cells have been reported not only in the presence of active tumor angiogenesis, but also in a broad spectrum of vascular disease with aberrantly increased angiogenesis, such as damage to the vessel wall caused by mechanical stress, ischemia, infection or autoimmune reactions [38, [78] [79] [80] . To assess whether the immature B cells population is also increased in mice that are tumor free but exhibit increased angiogenesis in a normal organ, we have employed the Rip1VEGF-E transgenic mouse model of upregulated angiogenesis in normal islets of Langerhans (Supplementary Figure 9A) . VEGF-E D1701 is a homologue of VEGF-A and a potent angiogenic factor binding exclusively to VEGFR-2 and Nrp1 and, thus, inducing endothelial cell proliferation, migration and sprouting [81, 82] . Rip1VEGF-E mice are characterized by increased endothelial cell proliferation in the islets of Langerhans of the pancreas, resulting in the formation of haemangiomalike structures (Fagiani et al., unpublished). We did not detect a significant increase in CD45 dim VR1 -CD31 low immature B cells in the peripheral blood of these mice as compared to non-transgenic control mice (Supplementary Figure 9B) , indicating that the levels of the surrogate marker cell populations are only increased by tumor-associated angiogenesis. In summary, we have identified an immature B cell population to represent a robust and general surrogate marker to monitor active tumor angiogenesis and the efficacy of anti-angiogenic therapy in diverse mouse models of cancer. These surrogate marker cells are readily quantifiable by flow cytometry in the peripheral blood of mice, and the markers used to define them are conserved in humans [83] . Hence, it will be interesting to monitor the levels of these or comparable cells in patients that are undergoing anti-angiogenic therapy, an effort that will require specifically designed clinical studies.
